Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Background: Goals of management in patients with heart failure and reduced ejection
fraction include reducing death and hospitalizations, and improving health status …

Aims This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of
dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF)> 40% varied by …

Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in
Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background: Effective therapies for HFrEF usually reduce NT-proBNP (N-terminal pro-B-type
natriuretic peptide) levels, and it is important to establish whether new treatments are …